Onxeo announces the great success of its share capital increase with shareholders’ preferential subscription rights

  • Total demand of Approximately 76.4 million euros, i.e. an oversubscription rate of 216% of the offer
  • Full exercise of the extension clause bringing the issue size to 40.7 million euros

Paris, (France), Copenhagen, (Denmark), December 12, 2014 – Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO or “the Company”) announces today the success of the capital increase with preferential subscription rights launched in France and in Denmark on November 17, 2014.

Following the subscription period, which ended on December 3, 2014, the total demand amounted to approximately €76.4 million, for an initial amount of €35.4 million, i.e. a global subscription rate of 216%:

  • 7,295,727 new shares were subscribed on an irreducible basis, representing approximately 92.7% of the new shares to be issued ; and
  • Reducible subscriptions amounted to 9,675,614 new shares and will, as a result, be satisfied only in part, i.e. for 1,757,833 new shares.

Consequently, the Company decided to fully exercise the extension clause of 15% of the size of the initial offer, raising the number of new shares to be issued from 7,872,661 to 9,053,560 shares. After the full exercise of the extension clause, the total gross proceeds of the transaction amounts to €40,741,020 issue premium included.

The Company’s share capital, following the capital increase, will amount to €10,136,051, represented by 40,544,204 shares with a par value of €0.25 each.

The settlement and delivery as well as the admission to trading on the regulated market of Euronext in Paris of the new shares are expected to take place on December 16, 2014. The new shares will carry full dividend rights. They will be immediately fungible with existing shares of the Company and they will be traded on the same trading line under the ISIN code FR0010095596.

The new shares will be admitted to trading and official listing on Nasdaq in Copenhagen on December 16, 2014 and will be delivered through VP Securities on December 18, 2014.

The share capital increase with shareholders’ preferential subscription rights was led by Natixis and Oddo & Cie acting as Joint Lead Managers and Joint Bookrunners of the transaction.

 Quote from Judith Greciet, CEO

  “The success of our share capital increase demonstrates our shareholders’ confidence and support to the Company’s growth strategy. We would like to warmly thank them and all investors who have subscribed to this transaction”, comments Judith Greciet, CEO of Onxeo.” This rights issue will allow us to accelerate and expand our development programs, pursuing thus the cornerstone achieved this year with the new European dimension of a merged company and an enlarged pipeline”. 

 Information available to the public

 The Prospectus filed with the Autorité des marchés financiers (the “AMF”) under visa number 14-600 dated November 17, 2014, consists of (i) ONXEO’s Document de Référence filed with the AMF on April 7, 2014 under number D.14-0303, (ii) ONXEO’’s Actualisation du Document de Référence filed on November 17, 2014 under number D.14-0303-A01, (iii) the Document E (including the summary of Document E) filed with the AMF on May 26, 2014 under number E.14-0034, (iv) a securities note and (v) a summary of the Prospectus (included in the securities note).

Copies of the Prospectus may be obtained free of charge at ONXEO’’s registered office, 49, boulevard du Général Martial Valin – 75015 Paris – France, on the Company’s corporate website (www.onxeo.com), on the AMF’s website (www.amf-france.org) and from the Joint Coordinators and Bookrunners.

A translation of the summary of the prospectus into Danish together with a non-binding translation into English of all the other documents constituting the prospectus have been prepared by the Company regarding the Danish offer. In case of discrepancies between the French prospectus and the English translation, the French version prevails. Such documents can also be obtained free of charge at Onxeo’s registered office, 49, boulevard du Général Martial Valin – 75015 Paris – France and on the Company’s corporate website (www.onxeo.com).

The Company draws investors’ attention to the risk factors described in chapter 5.2.1 of the Document de Référence, in chapter 4.2 of Document E and chapter 2 of the Securities Note.